Bank says Demant prognosis probably affected by component shortages

Uncertainties about the lack of components and transportation as well as increased investments are contributing factors dampening the profit outlook for Demant’s 2022, says analyst at Danish bank Sydbank.

by marketwire, translated by daniel pedersen

Demant has released its expectations for 2022, including an organic growth of 5–9 percent and an EBIT result of DKK 3.4–3.7bn (USD 521–567m), in connection with the full-year financial figures for 2021 on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Demant reports record operating result
For subscribers
Demant's 2022 growth prognosis to take center stage in full-year report after accidental release
For subscribers
Demant unveils parts of full-year report by mistake
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers
Novo Nordisk suffers Wegovy defeat to Viatris in patent court
It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees
The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.
For subscribers
Pharmaceutical industry to grow 4% annually towards 2030
However, there is one company in the manufacturing sector that is predicted to see negative growth.
For subscribers

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Photo: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers

Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr

Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers